Home › Funds › BIOS Capital Management, LP › IRD
BIOS Capital Management, LP position in IRD
OPUS GENETICS INC · Health Care
BIOS Capital Management, LP reported holding 3,683,429 shares of IRD (OPUS GENETICS INC) in its Q3 2026 13F filing — a position valued at US$17.83B, representing 52.17% of its reported portfolio and ranking #1 among its reported holdings. BIOS Capital Management, LP has disclosed IRD holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How BIOS Capital Management, LP's IRD position evolved
BIOS Capital Management, LP first disclosed a stake in IRD in Q4 2024 at 995,249 shares (US$1.2M). The position peaked in Q3 2026 at 3,683,429 shares, worth US$17.83B. Across 8 filings, BIOS Capital Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 3,683,429 shares valued at US$17.83B. Notable position changes include a 270% increase in Q2 2025 (shares rose 76% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 995.25K | $1.18M | New |
| Q1 2025 | 995.25K | $977.13K | Hold |
| Q2 2025 | 3.68M | $3.46M | Add |
| Q3 2025 | 3.68M | $6.59M | Hold |
| Q4 2025 | 3.68M | $7.40M | Hold |
| Q1 2026 | 3.68M | $16.76M | Hold |
| Q2 2026 | 3.68M | $15.14M | Hold |
| Q3 2026 | 3.68M | $17.83B | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IRD and 13F data
IRD (OPUS GENETICS INC) is a Health Care company. 69 other funds we track also report a position in IRD — the largest reported positions include Caligan Partners LP (US$25.0M), Nantahala Capital Management, LLC (US$22.1M), Boxer Capital Management, LLC (US$11.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IRD
- Caligan Partners LP 6.08M sh · $24.98M · Q2 2026
- Nantahala Capital Management, LLC 4.57M sh · $22.12M · Q3 2026
- Boxer Capital Management, LLC 2.81M sh · $11.57M · Q2 2026
- Trails Edge Capital Partners, LP 2.74M sh · $11.28M · Q2 2026
- GREAT POINT PARTNERS LLC 1.97M sh · $8.10M · Q2 2026
- Blue Owl Capital Holdings LP 969.61K sh · $4.69M · Q3 2026
- Opaleye Management Inc. 1.12M sh · $4.62M · Q2 2026
- Propel Bio Management, LLC 270.04K sh · $1.31M · Q3 2026
- Stonepine Capital Management, LLC 98.15K sh · $475.03K · Q3 2026
More on BIOS Capital Management, LP
FAQ
How long has BIOS Capital Management, LP held IRD?
BIOS Capital Management, LP has disclosed IRD holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is BIOS Capital Management, LP's current position in IRD?
As of Q3 2026, BIOS Capital Management, LP holds 3.68M shares of IRD (OPUS GENETICS INC), valued at $17.83B, representing 52.17% of its reported portfolio and ranking #1.
Has BIOS Capital Management, LP been buying or selling IRD?
In the latest 13F filing (Q3 2026), BIOS Capital Management, LP held unchanged its position in IRD. The position peaked in Q3 2026 at 3.68M shares.
Which other funds hold IRD?
Other major institutional holders of IRD include Caligan Partners LP, Nantahala Capital Management, LLC, Boxer Capital Management, LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.